Apoptosis in rectal cancer

Schwandner, O.; Schiedeck, Thomas; Bruch, Hans–Peter; Duchrow, M.; Windhoevel, U.; Broll, R.

doi:10.1007/bf02237426

Cited by 29 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may provide an explanation for the more aggressive nature of CRC in young Filipinos. Indeed, as Schwandner et al [24] found in their study, p53 was an independent predictor of recurrence and survival. In addition, Gallego et al [25] noted a significantly shorter disease-free survival for their p53-positive group.…”

Section: Discussionmentioning

confidence: 53%

Clinical and molecular biologic characteristics of early‐onset versus late‐onset colorectal carcinoma in Filipinos

Kaw

Punzalan

et al. 2004

World j. surg.

View full text Add to dashboard Cite

A case-control study of Filipino patients who underwent surgical resection for colorectal cancer (CRC) during a 1-year period was undertaken. Thirty-five patients under age 40 years were identified. Paraffin blocks of these and 35 randomly selected patients over age 40 underwent histologic and immunohistochemical evaluation. Markers chosen for evaluation included the apoptosis-associated gene products (p53 and bcl-2), a tumor proliferation activity-related factor (Ki-67), and the markers (MLH1 and MSH2) of DNA microsatellite instability (MSI). Results were correlated with age and the stage and location of the tumor. The average age of the early-onset group was 30.7 years compared to the late-onset group at 67.0 years; and the male/female ratio was equivalent. The younger patients had a significantly higher Dukes' stage, the tumors were more poorly differentiated, and they were more frequently of the mucinous and signet ring cell histopathologic type. Expression of p53 was higher in the younger patients ( p < 0.001) and was independent of the degree of differentiation or the stage of the tumor. No differences of expression were noted for the other markers measured. The increased frequency of CRC in Filipino patients less than 40 years of age offers a unique opportunity to gain a better understanding of carcinogenesis, which might be exploited during diagnosis and management. The differences noted between the early- and late-onset CRC are provocative and provide an impetus for increased screening in Filipinos.

show abstract

Section: Discussionmentioning

confidence: 53%

Clinical and molecular biologic characteristics of early‐onset versus late‐onset colorectal carcinoma in Filipinos

Kaw

Punzalan

et al. 2004

World j. surg.

View full text Add to dashboard Cite

show abstract

Apoptosis and its correlation with proliferative activity in rectal cancer

Kim

Lee

Chun

et al. 2002

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Adjuvant therapy for resectable rectal adenocarcinoma

Harrison

2000

Seminars in Surgical Oncology

View full text Add to dashboard Cite

The mainstay of treatment for rectal cancer over the past 100 years has been surgical resection. However, for the majority of rectal cancers treated conventionally by resection alone, locoregional recurrence is the major mode of failure. Over the past several decades, significant progress has been made in developing effective adjuvant regimens. In the United States, postoperative chemoradiation is standard treatment for T3 or node-positive patients. However, preoperative radiation with or without chemotherapy decreases local recurrence, increases sphincter preservation, and may improve survival. The purpose of this article is to review the role of adjuvant therapy in resectable rectal cancers and to update the status of ongoing randomized trials.

show abstract

Apoptosis in rectal cancer

Cited by 29 publications

References 29 publications

Clinical and molecular biologic characteristics of early‐onset versus late‐onset colorectal carcinoma in Filipinos

Clinical and molecular biologic characteristics of early‐onset versus late‐onset colorectal carcinoma in Filipinos

Apoptosis and its correlation with proliferative activity in rectal cancer

Adjuvant therapy for resectable rectal adenocarcinoma

Contact Info

Product

Resources

About